C-type lectin domain family 18 member B (CLEC18B)

C-type lectin domain family 18 member B (CLEC18B) is a protein-coding gene in the C-type lectin family, with predicted polysaccharide-binding activity and localization to intracellular organelles such as the Golgi apparatus, endosome, and sarcoplasmic reticulum, as well as activity in the extracellular space[2][5][6]. CLEC18B is upregulated in several cancer cell types, especially glioblastoma multiforme, where its high expression correlates with poorer patient survival, increased cell proliferation, migration, and invasion[1]. Functional studies show that CLEC18B knockdown suppresses these malignant properties and is linked to decreased Wnt/β-catenin signaling. While its precise physiological role remains to be fully clarified, CLEC18B shows potential as a prognostic biomarker and novel therapeutic target for glioblastoma and possibly other cancers[1][2][5]. CLEC18B is not yet the target of any known approved or investigational small molecules or biologics. The name is often pluralized (e.g., C-type lectin domain family 18), but the molecule described here is the specific "member B." No known misspelling or ambiguity in the target name. No known clinical safety concerns, as there are currently no drugs targeting CLEC18B. Nearly all functional, pathophysiologic, or prognostic evidence comes from cancer, especially glioblastoma multiforme[1].

Other names

CLEC18BMRLP1MRCL2UNQ306/PRO347Mannose receptor-like protein 1Mannose receptor-like 2secretory protein LOC497190

Not established; in GBM, siRNA knockdown of CLEC18B inhibits cell proliferation, migration, and invasion via downregulation of Wnt/β-catenin signaling pathway[1]